Study Of Safety And Efficacy Of Escitalopram Versus Sertraline In Major Depressive Disorder Patients: A Comparative Study.

[摘要] The study was aimed to study safety and efficacy of Escitalopram versus Sertraline in patients ofmajor depressive disorder patients attending Psychiatric OPD of S.N.M.C , AGRA This study wasconducted in the Department of Pharmacology and therapeutics in collaboration with the Department ofPsychiatry of Sarojini NaiduMedical College, Agra The selected patients of Major Depressive Disorderwere assigned randomly to receive either Escitalopram 10 mg or Sertraline 50 mg orallyonce daily andAnti-Anxiety medication like Alprazolam, Clonazepam, Etizolam, Lorazepam were added if required bythe clinician. The highest number of study subjects were observed to be in the age groupof31- 40 years(38.57 %).The lowest number of study subjects were observed to be in the age group of 51-55 years(5.71%).The chi-square value is 0.02 , df=1, the p value is 0.88 and the difference were found to bestatistically non-significant. Among70 study subjects, total 92.8 % and 7.2 % were having mild andmoderate HAM-D score at 12 weeks respectively and in group A study subjects 94.3 % and 5.7 % werehaving mild and moderate HAM-D score at 4 weeks respectively whereas group B study subjects 91.4 %and 8.6 % were having mild and moderate HAM-D score at 4 weeks respectively .Among total of 70 studysubjects, no subject were found to have severe symptoms in group A and group B after 12 weeks oftherapy. The chi-square value is 0.215 , df=1, the p value is 0.64 and the difference were found to bestatistically non-significant. The occurrence of adverse effects in group B was found to be numericallyhigher than group A and this difference was found to be statistically non significant (p=0.4). The studyconfirms that both Escitalopram and Sertraline are efficacious as the treatment of depressive disorder.There was no toxicity or major adverse drug reaction was observed during the study period in the groups.

[学科分类] 工程和技术（综合）

[关键词] Escitalopram;Sertraline;Safety;Efficacy;HDRS scale;UKU scale.